#News for #Investors: Our Co-founder and CEO, Harith Rajagopalan, M.D., Ph.D., will present at two upcoming investor conferences: Morgan Stanley Global Healthcare Conference Format: Fireside Chat Date: 09/06/2024 Time: 10:45 AM ET H.C. Wainwright 26th Annual Global Investment Conference Format: Company Presentation Date: 09/09/2024 Time: 2:00 PM ET Webcast replays will be accessible following the live sessions on the Events page of the Investors section on our website at https://ir.fractyl.com/.
Fractyl Health
Biotechnology Research
Lexington, MA 7,344 followers
Dedicated to novel therapeutic interventions that can reverse the metabolic disease epidemic.
About us
Fractyl Health is a leader in creating innovative therapies to address the root cause of type 2 diabetes. We were founded based on groundbreaking research and biological insights showing the key role of the intestine in metabolic control. Our therapies are uniquely designed to target and control this controller for the treatment of metabolic disease. Our lead program, Revita DMR, is a first-in-class procedural therapy that is now in late-stage clinical trials for the treatment of type 2 diabetes. Our team is made up of passionate innovators at the intersection of biology and technology, working to deliver better real-world outcomes for people with metabolic disease. Fractyl is located in Lexington, Mass.
- Website
-
http://www.fractyl.com
External link for Fractyl Health
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Lexington, MA
- Type
- Privately Held
- Founded
- 2010
Locations
-
Primary
17 Hartwell Avenue
Lexington, MA 02421, US
Employees at Fractyl Health
Updates
-
We're continuing to take steps to make a meaningful difference for #patients. Read more about Fractyl Health’s (#NASDAQ: GUTS) Q2 financial results and our potentially novel approach to weight maintenance here: https://bit.ly/3YJupri #FractylHealthNews
-
-
Exciting one-year follow-up data from #Germany shows positive results in lowering and maintaining both #WeightLoss and #BloodSugar. Learn more about the potential impact on people living with #obesity and #T2D: https://bit.ly/3AfB1DT #FractylHealthNews
-
-
#FractylHealthNews: We’re thrilled to share the FDA has granted Breakthrough Device Designation for Fractyl Health’s Revita in weight maintenance after discontinuation of #GLP1 drugs. This designation is given to expedite review of promising technologies that can improve the lives of people with life-threatening or debilitating conditions. Learn more: https://bit.ly/4c7ViZd
-
-
We had a wonderful time meeting with key stakeholders from around the world at this year’s American Diabetes Association (ADA) 84th Scientific Sessions. To read about the data we presented for our preclinical product candidate REJUVA® which was selected as the number one abstract out of 8,000 submissions by the Scientific Sessions Meeting Planning Committee, click here: https://lnkd.in/eTVrZWEf To hear a recap of our KOL event with Dr. David D’Alessio, visit the IR page on Fractyl.com. We look forward to seeing you again next year. *Rejuva is in preclinical development and has yet to be assessed by regulatory agencies #ADA2024 #ADAScientificSessions #Fractyl #obesity #type2diabetes #T2D #biotech
Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President’s Select Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions | Fractyl Health, Inc.
ir.fractyl.com
-
BREAKING NEWS: Fractyl Health is pleased to announce we will be accelerating our REMAIN 1 #clinicaltrial, studying our novel device’s efficacy in maintaining #weightloss following the discontinuation of GLP-1 therapy. We expect to report data starting in Q4 2024. We also announced an amendment to our REVITALIZE 1 study, expanding eligibility to patients with #T2D who are inadequately controlled on any glucose lowering agent – including GLP-1 agonists – increasing our potential treatment population in the United States by nearly six-fold. For the full #announcement, including a quote from our co-founder, read our full release: https://lnkd.in/gNS6D7DC
-
-
We’re thrilled to share that our oral presentation was chosen as noteworthy and one of eight Presidents’ Select Abstracts at this year’s @American Diabetes Association Scientific Sessions. Our co-founder and CEO Harith Rajagopalan shared exciting new preclinical data from our investigational #genetherapy program REJUVA®. For more information: https://lnkd.in/eTVrZWEf *Rejuva is in preclinical development and has yet to be assessed by regulatory agencies #ADASciSessions #ADA2024
-
-
Join us at the American Diabetes Association’s 84th Annual Scientific Sessions for a KOL discussion and Q&A session with Dr. David A. D’Alessio (Duke University School of Medicine) on Monday, June 24 from 7:00 AM – 8:00 AM ET. Our session will feature insights on the unmet medical need and evolving treatment landscape for patients living with #obesity and #T2D. Meet with several members from our management team who will discuss Fractyl’s novel platforms. RSVP to reserve your spot: https://lnkd.in/eig5dT8a A live webcast will be available on our website for those joining us virtually. #ADASciSessions #ADA2024
-
-
The American Diabetes Association (ADA) 84th Scientific Sessions starts today in Orlando, Florida. We will be presenting new preclinical data for our investigational product REJUVA® on Sunday, June 23rd, from 1:30-1:45 p.m. ET, in the Valencia Ballroom. This abstract was recognized as noteworthy and selected by the Scientific Sessions Meeting Planning Committee as one of eight President’s Select Abstracts. #ADA2024 #ADAScientificSessions #Fractyl #obesity #type2diabetes #T2D #biotech *Rejuva is in preclinical development and has yet to be assessed by regulatory agencies.
-
-
We are excited to join healthcare professionals and patients from around the world to learn more about the cutting-edge research and advancements in treatments at the American Diabetes Association (ADA) 84th Scientific Sessions, June 21-24, 2024, in Orlando, Florida. We will be presenting new preclinical data for our investigational product REJUVA® on Sunday, June 23rd, from 1:30-1:45 p.m. ET, in the Valencia Ballroom. This abstract was recognized as noteworthy and selected by the Scientific Sessions Meeting Planning Committee as one of eight President’s Select Abstracts. #ADA2024 #ADAScientificSessions #Fractyl #obesity #type2diabetes #T2D #biotech *Rejuva is in preclinical development and has yet to be assessed by regulatory agencies.
-